Biologic therapy for generalized pustular psoriasis: Real-world comparative effectiveness in a single-center - 04/12/25
Doi : 10.1016/j.jaad.2025.11.042
Zhongrui Xu, MD, Jiaqi Wang, MD, Yibo Wei, MD, Zhiguo Li, PhD, Yaxing Bai, MD, Gang Wang, MD, PhD ⁎ 
, Shuai Shao, MD, PhD ⁎
, Shuai Shao, MD, PhD ⁎ Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi, China
∗Correspondence to: Shuai Shao, MD, PhD, Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi’an, Shaanxi, ChinaXxx∗∗Gang Wang, MD, PhD, Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi’an, Shaanxi, ChinaXxx
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Thursday 04 December 2025
Key words : biologics therapy, generalized pustular psoriasis, IL-17A inhibitors, spesolimab, TNF-α inhibitors
| Drs Xu and Wang contributed equally to this work. |
|
| Funding sources: This study was supported by the National Natural Science Foundation of China ( 82322057 ). |
|
| Patient consent: Patients in this manuscript have given written informed consent to publication of their case details. |
|
| IRB approval status: This study was approved by the ethics committee of Xijing Hospital (KY20222202-X-1). |
|
| Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request, Shuai Shao ( shaos@fmmu.edu.cn ). |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?